New Drug Shows Promise in Treating Advanced Pancreatic Cancer
Recent early clinical trial results, presented at the EORTC-NCI-AACR Symposium in Barcelona, indicate that an experimental medication, daraxonrasib, when used in conjunction with standard chemotherapy, has effectively reduced tumor size or halted tumor growth in a significant majority of patients suffering from advanced pancreatic cancer.
Trial Overview and Patient Demographics
This phase 1/2 trial involved 61 patients who had advanced pancreatic cancer that had metastasized to other organs and had not previously undergone treatment for their condition. The study focused on the combination of daraxonrasib, administered orally on a daily basis, alongside two conventional intravenous chemotherapy agents: gemcitabine and nab-paclitaxel.
Impact of the Combination Therapy
Pancreatic cancer is known for its challenging treatment landscape, primarily because over half of the patients are diagnosed only after the disease has spread. Historically, major clinical trials show that chemotherapy alone reduces tumor size in approximately 23% to 42% of patients; however, cancer growth often resumes within five to six months, with an average survival rate of 8 to 11 months post-diagnosis.
In the recent study, which had a median follow-up of 18 months, tumors shrank in 60.7% of the cases, with complete disappearance in 8.2% of participants, while the combination therapy successfully halted tumor growth in 90.2% of the cohort.
Survival Rates and Efficacy
Patients experienced a median duration of 12.8 months before their condition worsened, nearly double the typical duration observed with standard chemotherapy. Additionally, 76.6% of the patients remained alive at the one-year follow-up mark.
Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center and the study’s lead investigator, stated, “We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year.”
Safety and Side Effects
While the treatment regimen led to some manageable side effects such as rash, diarrhea, fatigue, and low blood cell counts, only 5% of the participants discontinued the treatment due to adverse effects associated with daraxonrasib.
Mechanism of Action and Future Directions
Pancreatic cancers are predominantly driven by a malfunctioning gene known as RAS, which promotes continuous tumor growth. Daraxonrasib aims to inhibit this growth signal, a breakthrough that many researchers previously believed was unattainable through pharmacological means.
Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, noted that the results suggest that RAS-targeted therapies can be effectively integrated with existing treatments from the onset, potentially leading to longer-lasting therapeutic benefits.
Ongoing Research and Limitations
Researchers are conducting a larger, randomized Phase 3 trial, named RASolute-303, to directly compare the efficacy of daraxonrasib—both alone and in combination with chemotherapy—against standard chemotherapy. It is important to note that the current findings apply specifically to metastatic pancreatic cancer, and further studies will be required to explore the drug’s effectiveness in other cancers driven by similar RAS mutations.
The trial received funding from Revolution Medicines, the California-based company developing daraxonrasib, highlighting the potential of this new treatment approach in the ongoing battle against pancreatic cancer.


















Discussion about this post